fda shortage glp-1 to no longer allow compounding drugs Semaglutide Shortage Over? The FDA's

During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n).

However, due to the slimming properties of the drug, semaglutide is often abused by non-diabetics, non-obese individuals, and young people

BCBSM made a major announcement yesterday regarding GLP-1 coverage

Main outcome measures Hyperkalemia diagnosis in the inpatient or outpatient setting

When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes patent fight.

Learn about stomach issues all overlap and gastritis and reflux symptoms